Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated

NCT03457896 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT03457896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03457896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Unknown status
Start date
May 18, 2018
Completion date
September 30, 2022
Enrollment
35 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer